Results 151 to 160 of about 23,963 (194)

Siponimod inhibits disease-associated microglia-T cell interactions in chronic experimental autoimmune encephalomyelitis. [PDF]

Acta Neuropathol Commun
Husseini L, Geladaris A, Steinleitner MCJ, Häusler D, Weber MS.   +4 more
europepmc   +1 more source

Switch from fingolimod to ozanimod for safety or intolerance reasons. [PDF]

Ther Adv Neurol Disord
Signoriello E, Romano G, Foschi M, Zanghì A, D'Amico E, Fantozzi R, Centonze D, Lus G.   +7 more
europepmc   +1 more source

Evaluation of Selected Serum Adipocytokines in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Immunomodulatory Second-Line Drugs. [PDF]

Int J Mol Sci
Adamczyk B, Morawiec N, Kwinta R, Rakoca M, Wawrzyniak S, Zalejska-Fiolka J, Sowa A, Sawa K, Adamczyk-Sowa M.   +8 more
europepmc   +1 more source

Dermatologic findings after initiation of fingolimod in patients with multiple sclerosis: A real-world experience of five-year follow-up. [PDF]

Mult Scler J Exp Transl Clin
Samimi M, Sajedi A, Paybast S, Nabavi NS, Karimi S, Yazdanbakhsh S, Gaffari M, Najafian A, Faghani L, Zolfaghari Z, Vosough M, Nabavi SM.   +11 more
europepmc   +1 more source

A genome-wide CRISPR/Cas9 screen reveals novel positive regulators of FTY720 sensitivity in acute lymphoblastic leukemia cells. [PDF]

BMC Res Notes
Ferreira de Vasconcellos J, Friedman L, Satapathy I, Cubbage N, Palmer J, Majumder S, Kono M.   +6 more
europepmc   +1 more source

Serum visfatin in multiple sclerosis: distinct profiles in healthy controls, naive patients, and treated RRMS. [PDF]

Front Immunol
Mert S, Acır İ, Öztürk Emre H, Balcı K, Demir E.   +4 more
europepmc   +1 more source